Latest Seattle Cancer Care Alliance Stories
A roundtable dedicated to cancer survivorship at the NCCN 14th Annual Conference highlighted the need for transition care plans and improved physician/patient communication for cancer survivors.
Terminally ill patients and their family caregivers often feel abandoned by their doctors and feel a sense of "unfinished business" with them, according to a new study by an oncologist at the Seattle Cancer Care Alliance.
Distinguished Leadership Dedicated to Finding the Most Effective Means to Provide Health Care Access to Millions of Patients Who Seek Assistance Nationwide WASHINGTON, March 9 /PRNewswire-USNewswire/ -- The National Patient Advocate Foundation (NPAF) - a national, non-profit organization dedicated to the mission of creating avenues of improved patient access to health care through public policy reform at the state and federal levels - announced this month the election of four new Executive...
NCCN announces new modifications to the NCCN Guidelines for Colon and Rectal Cancers.
Updated guidelines for physicians that represent best practices for using magnetic resonance imaging (MRI) to newly diagnose breast cancer and to make treatment decisions for breast cancer were published today in the Journal of the National Comprehensive Cancer Network.
NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC).
A new method of characterizing breast lesions found during magnetic resonance imaging could result in fewer biopsies of benign tumors, U.S. researchers said. Dr.
Fitch Ratings has assigned an 'A+' rating to the expected issuance of approximately $90 million Washington Health Care Facilities Authority revenue and refunding bonds series 2008 on behalf of Seattle Cancer Care Alliance (SCCA). The Rating Outlook is Stable.
The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.